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Abstract
Introduction and hypothesis Variations in guidelines may result in differences in treatments and potentially poorer health-related
outcomes. We aimed to systematically review and evaluate the quality of national and international guidelines and create an
inventory of CPG recommendations on CPP.
Methods We searched EMBASE and MEDLINE databases from inception till August 2020 as well as websites of professional
organizations and societies. We selected national and international CPGs reporting on the diagnosis and management of female
CPP.We included six CPGs. Five researchers independently assessed the quality of included guidelines using the AGREE II tool
and extracted recommendations.
Results Two hundred thirty-two recommendations were recorded and grouped into six categories: diagnosis, medical treatment,
surgical management, behavioural interventions, complementary/alternative therapies and education/research. Thirty-nine
(17.11%) recommendations were comparable including: a comprehensive pain history, a multi-disciplinary approach, attributing
muscular dysfunction as a cause of CPP and an assessment of quality of life. Two guidelines acknowledged sexual dysfunction
associated with CPP and recommended treatment with pelvic floor exercises and behavioural interventions. All guidelines
recommended surgical management; however, there was no consensus regarding adhesiolysis, bilateral salpingo-
oophorectomy during hysterectomy, neurectomy and laparoscopic uterosacral nerve ablation. Half of recommendations (106,
46.49%) were unreferenced or made in absence of good-quality evidence or supported by expert opinion. Based on the AGREE
II assessment, two guidelines were graded as high quality and recommended without modifications (EAU and RCOG).
Guidelines performed poorly in the “Applicability”, “Editorial Independence” and “Stakeholder Involvement” domains.
Conclusion Majority of guidelines were of moderate quality with significant variation in recommendations and quality of
guideline development.
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Chronic pelvic pain (CPP) is a debilitating condition, affecting
15% of women worldwide [1]. It is associated with significant
socio-economic burden and long-term morbidity [2]. CPP is
defined as pain lasting > 6 months or recurrent episodes of
abdominal/pelvic pain, hypersensitivity or discomfort often
accompanied by elimination changes and sexual dysfunction
[3]. CPP remains a challenging disorder to treat because of the
complexities of pain sensation and unclear aetiology.
Standard medical and surgical treatments seldom prove effec-
tive at improving quality of life and pain intensity among
affected women [4]. Furthermore, the variation in outcome
reporting of trials evaluating interventions has prevented the
synthesis of data to identify effective treatments and draw
clinically relevant conclusions in the context of guideline for-
mation [5].
Clinical practice guidelines (CPG) are systematically de-
veloped statements using best available research evidence [6].
They aim to improve the delivery and quality of patient care
and health outcomes. Adoption of CPG attempts to eliminate
variation, standardize medical care and implement effective
treatments. Guidelines are developed using standardized
methods and processes including: engaging stakeholder
groups, identifying, quality assessment and synthesis of re-
search evidence as well using consensus methods to derive
robust guideline recommendations. The methodological qual-
ity of guidelines has been inconsistent [7–10].
Guidelines based on poor evidence or those that fail to
reflect the needs of women may contribute to the delivery of
suboptimal, ineffective or even harmful interventions thereby
compromising the quality of care. To date, there has been no
evaluation of the methodological quality of national or inter-
national guidelines on female CPP. In this systematic review,
we aimed to evaluate the methodological quality of CPP
guidelines, produce a comprehensive inventory of recommen-
dations and explore the relationships between recommenda-
tions and evidence.
Methods
This systematic review was designed and reported according
to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guideline [11]. It was performed
by a working group of CHORUS, an International
Collaboration for Harmonizing Outcomes in Research and
Standards in Urogynaecology and Women’s Health (https://
i-chorus.org). This study is part of a wider project for
establishing core outcome sets (COS) in CPP. We followed
a methodological approach implemented successfully by pre-
vious studies by CHORUS working groups appraising the
quality of clinical guidelines in various areas of gynaecology
[7, 8, 10].
Search strategy
A comprehensive literature search was undertaken using the
MEDLINE and EMBASE databases. Searches were per-
formed from database inception to August 2020 using the
following MESH terms: “chronic pelvic pain”, pelvic pain”,
“idiopathic chronic pelvic pain”, “guidance”, “guideline” and
“recommendation”. Reference lists of included guidelines
were hand-searched. We subsequently searched websites of
specialist societies and professional organizations including
gastroenterology, gynaecology, pain medicine and urology
to identify additional guidelines. (A list of these can be
found in Appendix 3.)
Selection of guidelines
We included guidelines reporting on the diagnosis and man-
agement of CPP in women. Two researchers (VG, VS)
reviewed the full text of retrieved guidelines independently
to assess eligibility. Guidelines in languages other than
English, specific to a particular condition (i.e. endometriosis,
bladder pain syndrome), local/regional guidelines or if an up-
dated guideline was available by the same organization were
excluded. We excluded editorials, reviews, position state-
ments, consensus statements, expert opinions, practice stan-
dards, practice alerts/bulletins and primary studies as these
documents do not meet the criteria of assessment or purpose
of the AGREE II tool [12]. Discrepancies regarding suitability
for inclusion were resolved by discussion with a senior author
(SKD) and a consensus reached. A PRISMA flow chart is
included to demonstrate the search and guideline inclusion
process (Appendix 2).
Data extraction
Two researchers (VG and VS) extracted guidelines character-
istics independently including: country of origin, year of pub-
lication, consensus methods, stakeholders involved, disease
area examined, description of database search, search terms
used, language restriction, date of searches, inclusion/
exclusion criteria and quality assessment instrument.
Two researchers (VG and VS) mapped recommendations
independently according to five pre-defined areas: (1) diagno-
sis, (2) medical management of pain, (3) surgical management
of pain, (4) behavioural interventions, (5) complementary and
alternative therapies for pain and (6) education and research.
We defined behavioural interventions as exercise, dietary
modification, physiotherapy and psychological treatment.
Complementary/alternative therapies were defined as acu-
puncture, dry needling, homoeopathy, massage, reflexology
and transcutaneous electric nerve stimulation (TENS). We
reported levels of evidence used to support recommendations
in guidelines. Supporting evidence was categorized according
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to the evidence-based medicine criteria [Cochrane reviews,
systematic review, randomized control trials (RCT), non-
randomized control trials, expert opinion and no reference].
Discrepancies were resolved by discussion with a third author
(SKD). In cases where a recommendation supported by mul-
tiple sources of evidence of varying quality, we documented
the highest quality of evidence.
Quality assessment of included guidelines
Five researchers (VG, VS, HJ, JL, SKD) were trained and
assessed the quality of guidelines independently using the
AGREE II tool. This is a validated instrument consisting of
23 items grouped into six quality domains and two further
global rating items: (1) scope and purpose (items 1–3), (2)
stakeholder involvement (items 4–6), (3) rigour of develop-
ment (items 7–14 items), (4) clarity of presentation (items 15–
17), (5) applicability (items 18–21) and (6) editorial indepen-
dence (items 22–23). Each item was rated using a seven-point
Likert scale from 1 (strongly disagree) and 7 (strongly agree)
[12]. The “Stakeholder Involvement” domain focuses on the
extent to which the guideline was developed by the appropri-
ate stakeholders and represents the views of its intended users
[12]. The “Editorial Independence” is concerned with the for-
mulation of recommendations not being unduly biased with
competing interests [12]. Refer to Appendix 1 for a detailed
description of each domain assessed by the AGREE II tool.
Data analysis
Domain quality scores were calculated by the summation of
scores per item and standardized using a prescribed equation
[12]. An overall guideline score was derived as a mean of all
six domain quality scores. This approach has been adopted by
previous studies using the AGREED II tool to evaluate clini-
cal guidelines [7, 13].
There is no consensus regarding using AGREE II scores to
differentiate between high- and low-quality guidelines or rec-
ommendation of guidelines. For the purpose of this study, we
considered a domain score < 50% as low quality [7, 10]. The
overall guideline score was used to categorize guidelines into
the following: low quality (0–30%), moderate quality (31–
60%) and high quality (61–100%) [7]. Based on these ratings,
high-quality guidelines were recommended, moderate quality
guidelines were recommended with modifications and low
quality guidelines were not recommended [9, 7].
Inter-rater reliability of assessments was tested for agree-
ment using the Fleiss’ kappa co-efficient. Scores of ≤ 0 indi-
cated no agreement, 0.01–0.20 indicated poor agreement,
0.21–0.40 indicated fair agreement, 0.41–0.60 indicated mod-
erate agreement, 0.61–0.80 indicated substantial agreement
and 0.81–1.0 indicated almost perfect agreement [14].
Tabulation and data
Descriptive statistics were calculated for all domains (median,
range and interquartile range). We used tables to map recom-
mendations, the supporting evidence for recommendations
and the hierarchy of evidence.
Patient and public involvement
There has been no patient involvement as this study is a sys-
tematic review of existing research.
Results
The electronic literature search yielded 1294 titles and ab-
stracts. We screened 639 titles and abstracts following the
exclusion of 655 duplicate records (Appendix 2 for
PRISMA flow chart). A further three guidelines were identi-
fied from examination of references lists and websites of
societies/associations (Appendix 3). In total, we included six
guidelines comprising four national and two international
guidelines: American College of Obstetricians and
Gynaecologists (ACOG), American Society of Reproductive
Medicine (ASRM), European Association of Urology (EAU),
International Society of Psychosomatic Obstetrics and
Gynaecology (ISPOG), Royal College of Obstetricians and
Gynaecologists (RCOG) and The Society of Obstetricians
and Gynaecologists of Canada (SOGC) (Table 1).
Although the ASRM guideline focused on women with
endometriosis, it also considers the wider issue and common
presenting complaint of female CPP. As our working group is
developing a COS on CPP, the consensus of the authors was
to include this guideline to provide a more comprehensive
inventory of CPP regardless of diagnosis.
The ACOG practice bulletin, although it is not titled a
CPG, was developed using methodology that met the criteria
of assessment by the AGREE II tool and was therefore
included.
The EAU guideline is directed to both women and men
with CPP. For the purpose of this study we excluded recom-
mendations that were relevant to men. However, this did not
impact the assessment of guideline development as the
AGREE II tool is an evaluation of the methods involved in
the development of guidelines rather than the recommenda-
tions themselves.
Guideline characteristics
Guidelines were published between 2002 and 2020. They
specifically reported on the management including treatment
of CPP. The number or type of stakeholders involved in the
development of guidelines was not reported by two guidelines
(ISPOG and RCOG). In four guidelines (ACOG, ASRM,
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EAU and SOGC), stakeholders included various health pro-
fessionals (gynaecologists, urologists, neurologist, gastroen-
terologist, pain medicine, psychologist and sexologist) and
methodological experts in clinical guideline development.
The number of stakeholders in these guidelines ranged from
12 to 52. No guideline reported the involvement of women
with CPP during the development process or reported their
experiences of the recommended interventions. All guidelines
developed recommendations applicable to high-income set-
tings. One guideline (ASRM) described consensus develop-
ment methods including the modified Delphi method. No
guidelines provided a detailed search strategy used to identify
supporting evidence for recommendations. Four guidelines
(ACOG EAU, RCOG and SOGC) described methods to qual-
ity assess research evidence (Table 1).
Methods on quality assessment of research evidence
Two guidelines were graded as high (EAU and RCOG) and
four guidelines were graded as moderate quality (ACOG,
ASRM, ISPOG and JOGC). The EAU and RCOG guidelines
scored highly with overall mean scores of 69.86% and
62.50% respectively. The remaining four guidelines scored





































































































(48.06%), ASRM (48.03%), SOGC (47.34%) and ISPOG
(31.55%) guidelines (Table 2).
Mean domain scores varied greatly from 13.16% to
81.11%. Guidelines performed best in the “Scope and
Purpose” (mean 81.11%, range 54.44–93.30) and “Clarity of
Presentation” (mean 76.85%, range 53.33–97.78) domains.
The ASRM and EAU guidelines achieved the highest scores
in the “Scope and Purpose” domain. The ACOG and EAU
guidelines achieved the highest scores in the “Clarity of
Presentation” domain (Table 2). Guidelines were of low qual-
ity in the “Applicability” (mean 13.61%, range 0.83–29.17),
“Editorial Independence” (mean 40.28%, range 0–91.67%)
and “Stakeholder Involvement” (mean 44.44%, range
14.44–60.00) domains. The ACOG, SOGC and ISPOG
guidelines recorded the lowest scores in these domains
(Table 2).
The Fleiss kappa index varied between 0.217 to 0.386 and
demonstrated fair agreement between reviewers (Table 2).
Recommendations for clinical practice
In total, we extracted 228 recommendations across six guide-
lines. We grouped recommendations into the following cate-
gories: diagnosis (96 recommendations), medical treatment
(72 recommendations), surgical treatment (29 recommenda-
tions), behavioural/physical interventions (18 recommenda-
tions), alternative treatments (7 recommendations) and
education/research (5 recommendations).
Overall, 39 recommendations (17.11%) were comparable
across guidelines including a comprehensive pain history,
multifactorial nature of CPP including attributing muscular
causes of CPP, an assessment of quality of life and multi-
disciplinary approach. There was significant variation in rec-
ommendations regarding hormonal treatment, role of surgical
interventions (adhesiolysis, hysterectomy, presacral
neurectomy and uterosacral nerve ablation) as well the effec-
tiveness of psychological and physical therapies.
Risks of interventions and procedures were reported in five
guidelines (ACOG, ASRM, EAU, SOGC and RCOG). The
rationale of clinical decision making was discussed in all
guidelines,
Diagnosis
Ninety-seven recommendations regarding diagnosis and in-
vestigation of CPP were made across guidelines. Of these,
39 recommendations (40.21%) were comparable across all
six guidelines. Included guidelines described the multifactori-
al nature of CPP including causes such as bladder pain syn-
drome (BPS), irritable bowel syndrome (IBS) and muscular/
myofascial dysfunction. All guidelines attributed CPP to
muscular/myofascial causes including trigger points.

















































































































































































































































































































































































































































































































































































































































































































were featured in five guidelines (ACOG, ASRM, EAU,
ISPOG and RCOG). Three guidelines referred to endometri-
osis (ASRM, ISPOG and RCOG) and four guidelines alluded
to nerve damage (ACOG, EAU, ISPOG and RCOG). IBS was
described as a contributing factor by three guidelines (ACOG,
ASRM and RCOG).
A detailed pain history was recommended by all guide-
lines; however, only two guidelines suggested a visual ana-
logue scale (VAS) to measure pain intensity (ISPOG and
SOGC). All guidelines recommended the evaluation of psy-
chosocial factors including the recognition of concomitant
mood disorders and assessment of quality of life. However,
no guideline specified which patient-reported outcome mea-
surement instrument to utilize.
Investigation of CPP varied among guidelines. The role of
imaging such as transvaginal ultrasound to exclude
adenomyosis, adnexal masses and endometriosis was recom-
mended by three guidelines (ASRM, ISPOG and RCOG).
MRI was recommended by the RCOG guideline to diagnose
adenomyosis; however, its ability to accurately detect
endometriotic deposits was uncertain (ASRM and RCOG).
Diagnostic laparoscopy was recommended by five guidelines
(ASRM, EAU, ISPOG, RCOG, SOGC). However, the RCOG
guideline suggested laparoscopy as a second-line investiga-
tion if other therapeutic interventions fail. Cystoscopy was
recommended by the SOGC guideline only.
A multi-disciplinary and multi-speciality approach to pain
management was explicitly stated by five guidelines (ACOG,
EAU, ISPOG, RCOG and SOGC). Furthermore, the ACOG,
ISPOG and EAU guidelines also recommended that care of
patients with CPP should be undertaken by pain medicine
specialists.
Medical treatment
Seventy-two recommendations were extracted regardingmed-
ical treatment of CPP. No recommendations were comparable
in this domain. Nineteen recommendations focused on anal-
gesia. Treatments with the highest grade of recommendations
(i.e. level of evidence 1a and grade A recommendation) were
paracetamol, NSAIDs (non-steroidal anti-inflammatory
drugs), gabapentin, antidepressants, topical capsaicin and opi-
oids (Table S3).
Simple analgesia including paracetamol and NSAIDs was
specifically recommended by two guidelines (EAU and
ASRM). The use of anticonvulsants such as pregabalin and
gabapentin to treat CPP was described by four guidelines
(ACOG, EAU, ISPOG and SOGC). Pain management with
opioids was described by two guidelines (EAU and SOGC).
However, only the EAU guideline stated which opioid to use,
the preferred route of administration, a detailed consenting
process including risks of addiction and dependency as well
as plans for monitoring. In comparison, the ACOG guideline
did not recommend treatment of CPP using opioids. Adjuvant
medications such as tricyclic anti-depressants were suggested
by four guidelines (ACOG, EAU, ISPOG and SOGC).
Hormonal treatment was recommended for underlying
gynaecological causes such as endometriosis by three guide-
lines (ASRM, SOGC and RCOG). The use of oral contracep-
tives as a first-line treatment was stated by two guidelines
(ASRM and SOGC). Progestins, Danazol and GnRH ana-
logues were considered as first-line treatments in women with
suspected endometriosis by the SOGC guideline. The ASRM
guideline considered these as second-line treatments and rec-
ommended that an alternative diagnosis should be sought if
adequate pain relief was not achieved. The RCOG also rec-
ommended hormonal treatment however did not specify
which agents. A diagnostic laparoscopy was recommended
in instances where pain was refractory to hormonal treatment
after 3 to 6 months (Table S3).
Disease-specific treatments were described for BPS, chron-
ic anal pain syndrome, irritable bowel syndrome (IBS) and
myofascial dysfunction by four guidelines (ACOG, ASRM,
EAU and SOGC). For suspected IBS, antispasmodics were
recommended by one guideline (RCOG). A comprehensive
list of BPS treatments including lifestyle modifications, oral
medications, neuromodulation, intravesical therapies includ-
ing trigonal and submucosal injections as well as
hydrodistension was detailed by one guideline (EAU).
Management of chronic anal pain syndrome using inhaled
salbutamol, botulinum toxin A, electrogalvanic stimulation
and percutaneous tibial nerve stimulation was described by
the EAU guideline (Table S3).
Surgical treatment
This domain consisted of 29 recommendations. However,
no recommendations were comparable despite surgical
management described by all guidelines. Twenty-four rec-
ommendations specifically referred to surgical procedures.
The highest grade of recommendations supported hyster-
ectomy for refractory symptoms, hysterectomy with ovar-
ian conservation for endometriosis/adenomyosis and treat-
ment of peritoneal pockets frequently associated with en-
dometriosis and did not support routine adhesiolysis
(Table S4). It must be noted that recommendations were
graded A or B and the level of evidence varied between I to
II-2. One guideline did not describe a level of evidence
supporting recommendations (ACOG). No recommenda-
tion of the highest grade (i.e. level of evidence I and grade
A) was noted in the surgical domain (Table S4).
Hysterectomy was recommended by three guidelines for
refractory and severe symptoms (ASRM, ISPOG and
SOGC). One guideline advised bilateral salpingo-
oophorectomy during hysterectomy to relieve symptoms such
as CPP secondary to endometriosis (ASRM). In contrast, the
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SOGC guideline suggested ovarian conservation was an ac-
ceptable option during hysterectomy for adenomyosis/endo-
metriosis. The use of HRT after hysterectomy and bilateral
oophorectomy for CPP secondary to endometriosis was de-
scribed by a single guideline (SOGC).
Presacral neurectomy and laparoscopic uterosacral nerve
ablation were discussed by two guidelines (ASRM and
SOGC). The ASRM guideline did not recommend these in
instances of endometriosis-related CPP. However, it did sug-
gest that presacral neurectomy may be beneficial in reducing
the severity of dysmenorrhoea. The SOGC guideline stated
the role of presacral neurectomy for pain reduction in endo-
metriosis remained unclear (Table S4).
There was a difference in recommendations regarding
adhesiolysis. Laparoscopic adhesiolysis was supported by
the ISPOG guideline; however, the SOGC and ACOG guide-
lines did not recommend routine laparoscopic adhesiolysis in
the context of CPP. The RCOG guideline recognized the ben-
efit of dividing dense vascular adhesions to reduce pelvic pain
but did not support adhesiolysis of fine adhesions (Table S4).
Three guidelines (ASRM, ISPOG and SOGC) recom-
mended surgical treatment of endometriosis using laparoscop-
ic ablation or excision. A single guideline (EAU) described
sacral neurostimulation for chronic anal pain syndrome.
Transurethral resection of bladder lesions in type 3 BPS was
recommended by the EAU guideline. Ablative surgery for
BPS was advised by a single guideline as a last resort and
by knowledgeable surgeons only (EAU) (Table S4).
Behavioural/physical interventions
Eighteen recommendations described behavioural interven-
tions. No recommendations were comparable across guide-
lines. The highest grade (i.e. level of evidence I and grade
A) of recommendations supported psychological interven-
tions combined with medical/surgical, biofeedback treatment
in pelvic pain and dyssynergic defecation and biofeedback as
an adjunct to muscle exercises in overactive pelvic floor mus-
cles (Table S5).
Psychological treatments were recommended by three
guidelines (ACOG, EAU and ISPOG). The EAU and
ISPOG guidelines recommended integrating psychological
interventions with standard medical/surgical treatments for
CPP. The EAU guideline specifically referred to the role of
psychological treatment in various conditions including PBS,
urethral pain syndrome and chronic vulvar pain.
The ACOG guideline recommended cognitive behavioural
therapy, pelvic floor physiotherapy or sexual therapy alone or
in combination to manage myofascial dysfunction and
dyspareunia secondary to CPP. Only one guideline (EAU)
recommended training pelvic floor muscles to improve quality
of life and sexual function. The EAU guideline advocated
using behavioural strategies for patients and their partners
with sexual dysfunction secondary to CPP.
Physiotherapy was recommended by a single guideline
(EAU) for BPS and pelvic floor overactivity. Pelvic floor
muscle treatment was considered a first-line treatment in
CPP by the EAU guideline.
Only one guideline (SOGC) reported the use of exercise in
the treatment of CPP due to myofascial dysfunction. No fur-
ther details regarding the type of exercise (aerobic or resis-
tance) were provided (Table S5).
Complementary and alternative treatments
Seven recommendations focused on alternative treatments.
No recommendations were comparable across guidelines.
The highest grade (i.e. level of evidence I and grade A) of
recommendations supported treatment of myofascial trigger
points by dry needling or pressure (Table S5). There were
conflicting statements regarding dry needling of trigger points
(EAU and ISPOG).
One guideline reported limited data supporting the use of
alternative therapies to treat CPP including acupuncture, trig-
ger point treatment, reflexology, biofeedback, distension ther-
apy, homoeopathy and Thiele massage (ISPOG). A single
guideline (EAU) supported the use of alternative therapies
such as TENS to treat CPP. There were no consistent recom-
mendations regarding acupuncture and use was limited to spe-
cific clinical scenarios. The EAU guideline did not recom-
mend acupuncture in the treatment of BPS. However, the
ACOG guideline supported use of acupuncture in CPP sec-
ondary to muscoskeletal aetiology (Table S5).
Recommendations for education and research
Five recommendations were relevant to education and re-
search. No recommendations were comparable in this domain.
One guideline advised incorporating CPP into the curricula of
health professionals (SOGC). Two guidelines outlined future
research priorities including the role of gene therapy, effec-
tiveness of surgical management and investigating myofascial
and sexual dysfunction in CPP (EAU and SOGC).
Evidence supporting recommendations
Three guidelines (EAU, RCOG and SOGC) reported the grad-
ing of evidence used to support recommendations. Each
guideline used a different grading scale including the Oxford
Centre for Evidence-based Medicine Levels of Evidence
(EAU), the Scottish Intercollegiate Guidelines Network
(SIGN) grading system (RCOG) and the Canadian Task
Force on Periodic Health Exam grading (SOGC). Of note,
the ACOG guideline evaluated evidence using the US
Preventative Services Task Force grading system; however,
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the level of evidence supporting each recommendation was
not reported.
The total number of references cited in guidelines ranged
from 22 to 644. The number of Cochrane reviews cited by
each guideline ranged from 1 to 20. One guideline did not use
any Cochrane reviews to support recommendations. The total
number of RCTs used per guideline ranged from 6 to 32.
Almost half of the recommendations (106, 46.49%) were
unreferenced, made in the absence of good quality evidence
or supported by expert opinion.
Discussion
Main findings
There is significant variation in CPP guideline quality and
recommendations. We identified 189 unique recommenda-
tions but only 39 recommendations were comparable across
6 guidelines. A lack of consensus was observed in recommen-
dations regarding medical and surgical treatments as well as
complementary/alternative therapies. Nearly half of recom-
mendations (108, 46.55%) were unreferenced, or made in ab-
sence of good quality evidence or supported by expert opin-
ion. The quality of guidelines was variable; only two guide-
lines were assessed as high quality using the AGREE II in-
strument. Guidelines performed poorly in the “Applicability”,
“Editorial Independence” and “Stakeholder Involvement”
domains.
Strength and limitations
To our knowledge, this is the first study to systematically
appraise the methodological quality and map recommenda-
tions of CPP guidelines. We used robust and reproducible
methods that have been successfully implemented in previous
studies. To improve the scientific rigour of this review, five
reviewers trained in using the AGREE II tool assessed guide-
lines, thereby minimizing possible bias arising from data col-
lection or inherent limitations of the AGREE II tool related to
inter-observer variations. Nevertheless, the inter-rater agree-
ment among reviewers was fair.
This study has limitations. The AGREE II instrument is
used to assess the rigour of guideline development rather than
the quality of guideline content. Scoring achieved using the
AGREED II tool is not a reflection of applicability or imple-
mentation in clinical practice [15]. All reviewers were from
the same medical speciality and this may have influenced
scores assigned to guidelines. However, as our focus was fe-
male CPPwe feel that the clinical and research expertise of the
assessors may counteract this limitation. Our research group
included individuals with clinical expertise in minimal access
gynaecological surgery (HJ and VG), reproductive medicine
and surgery (VS) and urogynaecology (JL and SKD), thus
providing different clinical perspectives from sub-specialities
within gynaecology. Our ability to synthesize and compare
recommendations was limited by the varied scope and small
number of guidelines. However, by including guidelines that
are diverse may provide a comprehensive and informative
overview of available guidance. We included guidelines pub-
lished between 2002 and 2018. However, only two guidelines
(ACOG and SOGC) were published after the introduction of
standardized terminology in CPP syndromes [3]. The use of
standardized terminology can help improve identification, di-
agnosis and treatment. Our understanding and approach to
CPP is an evolving process; however, guidelines may not be
an accurate reflection if they are not updated regularly.
Interpretation
This systematic review reflects variations in guideline recom-
mendations and the poor quality of guideline development.
Similar results were found in studies critically appraising the
quality of guidelines including BPS, endometriosis, obstetric
perineal lacerations and the use of transvaginal mesh implants
in prolapse [7, 8, 10, 16]. Challenges of guideline develop-
ment are not unique to a specific area of medicine but repre-
sent a generic issue arising from a lack of standardization. Our
findings contribute to the existing body of evidence
supporting the need to harmonize national and international
guidelines. A coordinated and collaborative approach is re-
quired among guideline developers. Guidelines should be de-
veloped using transparent and robust methods such as those
outlined by the AGREE II tool. This will facilitate the com-
parability and harmonization of guidelines and their recom-
mendations as differences in guideline development methods
can result in varying recommendations. Standardized guide-
line development will minimize any unwarranted and unjusti-
fied variations in clinical practice.
Various terminology has been used by authors and organi-
zations to describe clinical practice recommendations. These
have included clinical practice guidelines, consensus state-
ments, position statements, practice alerts and hybrid terms
such as consensus guidelines. Such terms can be indicative
of the level of evidence and strength of recommendations.
However, authors have used these terms interchangeably with
a lack of consistency and available evidence. This poses a
particular problem and possibly a challenge in harmonization
of clinical guidance, as encountered in this study, of identify-
ing “true” clinical practice guidelines that are developed using
rigorous methodology. The use of inconsistent terminology
may mislead clinicians about the level of confidence to place
in recommendations and the process by which they were de-
veloped. Further consensus initiatives are needed for transpar-
ency and clarity regarding the definitions of these terminolo-
gies [17].
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Guidelines support and provide an evidence base to the
clinical decisions made in daily practice. However, we ob-
served that almost half of all recommendations were made
despite the absence of good quality evidence. The shortage
of primary research supporting the management of women
with CPP may prohibit the development of useful guidelines
[18]. Furthermore, the quality of existing RCTs evaluating
CPP interventions is variable with significant variability in
outcome selection and reporting [5]. A working group within
CHORUS is currently in the progress of establishing core
outcome sets (COS) in CPP. Implementation of a COS will
promote greater reporting consistency and reduce outcome
reporting bias by stipulating a minimum set of criteria to re-
port. It will also facilitate the comparability and synthesis in
meta-analysis to produce high-quality results leading to in-
formed healthcare decisions.
Diagnostic and therapeutic guideline recommendations are
helpful in standardizing and improving the quality of care.
However, they are limited and may not be relevant or apply
in every clinical field of practice. CPP is a manifestation
resulting from various underlying conditions that may evolve
and develop into regional pain disorders. The complex
aetiology of CPP and scarcity of available evidencemay cause
clinicians to resort to their own experience or seek expert
opinions. A holistic approach is needed as underlying causes,
treatment options and concerns of women with CPP can vary.
Additionally, groups/societies publish guidelines for their
members rather than a broader audience. The focus and scope
of guidelines may be influenced by the clinical/scientific
theme, interests or priorities of publishing societies/
professional groups. For example, professional bodies for
gynaecologists may focus on endometriosis only in women
presenting with CPP. This may have contributed to the vari-
ability of recommendations for the management of female
CPP observed in this study. The inclusion of a multidisciplin-
ary stakeholder committee will help produce concise and col-
laborative recommendations that prevent duplicate investiga-
tions and the recommendation of ineffective treatments. This
study indicated that guidelines performed poorly in the
Stakeholder Involvement domain reflecting unilateralism in
their approach to CPP including a lack of engagement and
participation with their target audience, i.e. women with CPP.
In this review, all guidelines recommended surgical inter-
vention; however, there was no consensus among guidelines.
The lack of consistent recommendations presents difficulty
when supporting or refuting the effectiveness of surgical pro-
cedures, such as adhesiolysis, to manage female CPP. The
benefit of bilateral salpingo-oophorectomy during hysterecto-
my was also unclear with contradictory advice given in two
guidelines. There is a place for hysterectomy in the manage-
ment of CPP particularly due to endometriosis; however, pa-
tient selection is paramount [19]. Furthermore, recent studies
have shown that bilateral removal of normal ovaries during
hysterectomy does not result in improved outcomes but in fact
is associated with increased morbidity [19–21]. Guidelines
should not only focus on identifying effective interventions
by utilizing the best available evidence but also provide guid-
ance on which patient factors may contribute to the success
and failure of such interventions [22].
In an era of patient-centred care, it was concerning that no
guideline reported including women with CPP in the devel-
opment process. Views and perceptions of women with CPP
can be incorporated to frame the overarching theme of future
guidelines as well as ensure the quality and relevance of rec-
ommendations. For example, all guidelines discussed the as-
sociation of sexual abuse and CPP. However, no guideline
specifically outlined recommendations pertaining to sexual
abuse. Furthermore, no guideline reported women’s experi-
ences to support the use of recommended interventions.
These insights are invaluable for policymakers and guideline
developers. The identification of barriers and facilitators can
influence the successful implementation of interventions. In
this review, included guidelines may not have incorporated
qualitative research findings because of a lack of primary
qualitative studies exploring the experiences of women with
CPP [18, 23].
The detrimental impact of CPP on quality of life outcomes
has been described and identified as a priority for women with
CPP [18]. Despite this, quality of life assessment is only re-
ported by half of RCTs evaluating treatments for CPP [5]. Our
findings demonstrated that all guidelines referred to the mea-
surement of quality of life; however, there was no recommen-
dation regarding which measurement instrument to utilize.
Our previous systematic review identified 17 quality of life
measurement instruments; however, further research is re-
quired to assess the validity of such instruments in a CPP
population [5].
There is an increased prevalence of sexual dysfunction ob-
served in women with CPP compared with those without CPP
(69.6% versus 30.4%) [24]. Underlying pelvic floor dysfunc-
tion including pelvic floor muscle overactivity and myofascial
trigger points have been implicated in sexual disorders.
Despite the impact of sexual dysfunction on the psychological
and emotional well-being of women, we only identified two
guidelines that recognized concurrent sexual dysfunction in
women with CPP [25]. The ACOG and EAU guideline rec-
ommended pelvic floor physiotherapy to improve quality of
life and sexual function. Although there is increasing evidence
to support the use of physiotherapy in CPP and sexual dys-
function, it remains underused in clinical practice [26].
Similarly, exercise has been successfully incorporated into
multidisciplinary treatment programmes to treat female CPP
[4, 27]. Available evidence suggests that physical activity/
exercise as an intervention is associated with few adverse
events and may improve pain intensity, physical function
and consequently quality of life [28]. However, our study
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demonstrated that only one guideline recommended the use of
exercise in the management of CPP despite such benefits.
Guideline developers need to incorporate multidisciplinary
treatment modalities such as physiotherapy and exercise to
maximize treatment benefits derived from conventional
medical/surgical interventions.
Our findings are consistent with other studies that noted the
Applicability, Editorial Independence and Stakeholder
Involvement domains as areas of improvement for future
guideline development [7, 8, 10, 16].
Our findings suggest that guidelines performed poorly in
the Stakeholder Involvement domain. Guidelines failed to en-
gage and involve women with CPP in the development pro-
cess. Most guidelines were unsuccessful at including individ-
uals from relevant professional groups therefore narrowing
their scope to managing CPP. For example, only a single
guideline included health professionals from various disci-
plines such as gastroenterology, neurology, pain medicine,
urology and psychology. The inclusion of a multidisciplinary
guideline development group will help produce concise and
collaborative recommendations. Furthermore, in complex
conditions such as CPP which may be due to a single or
multiple concurrent causes or indeed idiopathic, input from
multiple specialities is required. It is vital that clinical path-
ways are efficient and coordinated. A diagnostic pathway can
often be a frustrating and negative experience for women with
CPP hindered by delay [18]. Guideline developers such as the
National Institute of Clinical Excellence (NICE) have initia-
tives such as the Patient Public Involvement Programme
(PPIP) to support opportunities for patients and the public to
be involved in developing guidance. Additionally, guideline
developers can contact patient organizations to assist with the
recruitment and inclusion of patients on their panels.
The Applicability domain refers to the implementation of
guideline recommendations. Various factors can influence the
successful implementation of guidelines such as the aware-
ness of recommendations, associated costs and resource im-
plications. Development of guidelines without effective and
structured implementation strategies may not lead to the ex-
pected changes in clinical practice. Identification of barriers
and facilitators in advance and incorporating these into the
guideline development process can lead to tailored implemen-
tation strategies. These can improve adherence and avoid un-
necessary investigations and inadequate interventions [29].
Maintaining editorial independence is vital to ensure the
reliability and validity of recommendations. Influence or in-
terference from funding bodies or conflicts of interest from
members of the guideline development group can introduce
bias and undermine the credibility of the guideline develop-
ment process. Conflicts of interest can be mitigated by guide-
line developers obtaining and presenting full and transparent
disclosures.
Conclusion
The majority of guidelines were of moderate quality with sig-
nificant variation in recommendations and the quality of
guideline development. Adoption of standardized guideline
development methods will ensure guideline recommendations
are relevant, reliable and transferrable to clinical practice.
Appendix 1
Table 3 AGREE II domains and
definitions Domain Definition




Focuses on extent to which guideline was developed by appropriate stakeholders and
represents the views of its intended users
3. Rigour of
Development
Relates to the process used to gather and synthesize the evidence, the methods to
formulate the recommendations and to update them
4. Clarity of
Presentation
Deals with the language, structure and format of the guideline
5. Applicability Pertains to the likely barriers and facilitators to implementation, strategies to improve
uptake and resource implications of applying the guideline
6. Editorial
Independence



























Addional records idenfied 
through other sources
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reading tle or abstract
(n = 630)
Full-text arcles assessed 
for eligibility
(n = 21)
Full-text arcles excluded, 
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Prostate related – (1)
Non-specific pain- (2) 
Not in English (1)
Unable to obtain full text 
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Studies included in 
qualitave synthesis
(n = 6)
Fig. 1 PRISMA flow diagram
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Appendix 3. List of specialist society websites
searched
American Association of Family Practice (AAFP).
American College of Obstetricians and Gynaecologists
(ACOG).
British Association of Urological Surgeons (BAUS).
British Fertility Society (BFS).
British Society of Gastroenterology (BSG).
British Society of Gynaecological Imaging (BSGI).
British Society of Gynaecological Endoscopy (BSGE).
British Society of Pain (BPS).
British Society Psychosomatic Obstetrics, Gynaecology
and Andrology (BSPOGA).
British Society of Urogynaecology (BSUG).
British Society of Biopsychosocial Obstetrics and
Gynaecology.
Institute of Psychosexual Medicine.
eGuidelines.co.uk
European Association of Urology (EAU).
European Society of Gastroenterology (ESGE).
European Society of Gynaecology.
European Society Gynaecological Endoscopy (ESGE).
Faculty of Pain Medicine.
Indian College of Obstetricians and Gynaecologists
(ICOG).
International Association for the study of pain.
International Federation of Gynaecology and Obstetrics
(FIGO).
International Urogynecology Association (IUGA).
National Institute of Clinical Excellence (NICE).
Royal Australian and New Zealand College of Obstetrics
and Gynaecology (RANZOG).
Royal College of Obstetricians and Gynaecologists
(RCOG).
Scottish Intercollegiate Guidelines Network (SIGN).
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